M
Michael S. Gordon
Researcher at Pinnacle Financial Partners
Publications - 172
Citations - 13887
Michael S. Gordon is an academic researcher from Pinnacle Financial Partners. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 43, co-authored 153 publications receiving 12207 citations. Previous affiliations of Michael S. Gordon include GlaxoSmithKline & Indiana University – Purdue University Indianapolis.
Papers
More filters
Journal ArticleDOI
A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors.
Howard A. Burris,Michael S. Gordon,Matthew D. Hellmann,Patricia LoRusso,Leisha A. Emens,F. Stephen Hodi,Christopher H. Lieu,Jeffrey R. Infante,Frank Tsai,Joseph Paul Eder,James M. Cleary,Danijela Jelovac,Amy Lew Tsuhako,Lars Mueller,Ray S. Lin,Kari M. Morrissey,Sami Mahrus,Roland Morley,Andrea Pirzkall,Sarah Lindsey Davis +19 more
TL;DR: GDC-0919, a small molecule inhibitor of indoleamine-2,3-dioxygenase 1 (IDO1), reduces tryptophan catabolism and kynurenine production within the tumor microenvironment that may promote normal effector T cell activity and an immunogenic state.
Journal ArticleDOI
Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995.
Michael S. Gordon,Molly L Young,Martin S. Tallman,Larry D. Cripe,John M. Bennett,Elisabeth Paietta,Walter L. Longo,Henry Gerad,Joseph J. Mazza,Jacob M. Rowe +9 more
TL;DR: 2-CdA as a single agent, in the doses used in this study, is ineffective therapy for relapsed or refractory AML, though bone marrow aplasia was achieved in eight patients.
Journal ArticleDOI
Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors
Mark A. Dickson,Mark A. Dickson,Michael S. Gordon,Gerald Edelman,Johanna C. Bendell,Ragini R. Kudchadkar,Patricia LoRusso,Stuart Johnston,Douglas O. Clary,Gary K. Schwartz +9 more
TL;DR: XL281 was generally well tolerated and the MTD was established at 150 mg/day and partial responses and clinical benefit were observed in several patients.
Proceedings ArticleDOI
Abstract B79: A first-in-human Phase 1 study of anti-cancer stem cell (CSC) agent OMP-54F28 (FZD8-Fc) targeting the WNT pathway in patients with advanced solid tumors.
David Smith,Michael S. Gordon,Wells A. Messersmith,Rashmi Chugh,David S. Mendelson,Jakob Dupont,Robert Joseph Stagg,Ann M. Kapoun,Lu Xu,Rainer K. Brachmann,Antonio Jimeno +10 more
TL;DR: A first-in-human Phase 1 study of anti-cancer stem cell (CSC) agent OMP-54F28 (FZD8-Fc) targeting the WNT pathway in patients with advanced solid tumors results in well tolerated dose, safety, pharmacokinetics, and anti-tumor activity.
Journal ArticleDOI
Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE).
Matthew R. Smith,Christopher Sweeney,Dana E. Rathkopf,Howard I. Scher,Christopher J. Logothetis,Daniel J. George,Celestia S. Higano,Evan Y. Yu,Andrea L. Harzstark,Eric J. Small,A. Oliver Sartor,Michael S. Gordon,Nicholas J. Vogelzang,David Smith,Maha Hussain,Johann S. de Bono,Naomi B. Haas,Christian Scheffold,Yihua Lee,Paul G. Corn +19 more
TL;DR: This is a NRE cohort in docetaxel (D)-pretreated pts with a novel primary endpoint of bone scan response based on computer-aided quantitative assessment ofBone scan lesion area (BSLA) and a double-reader, independent, blinded review.